StockData
Nyxoah SA logo

Nyxoah SA (NYXH) company profile

NYXHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 26, 2026Score 1/30
$0.86−0.04 (-4.10%)

Close on Nov 18, 2026Market cap $37.13MP/E –Yield –

About Nyxoah

Surgical & Medical Instruments & Apparatus, SIC 3841

Nyxoah is a medical technology company focused on developing and commercializing therapeutic solutions for obstructive sleep apnea. Its primary product is the Genio system, a leadless hypoglossal neurostimulation device that delivers bilateral stimulation to keep upper airways open during sleep. The system is implanted through a single incision under the chin and operates using an external power source. The company primarily targets adult patients diagnosed with moderate to severe obstructive sleep apnea who cannot tolerate, fail, or refuse positive airway pressure therapies, marketed through hospitals and physicians such as sleep specialists and ear, nose, and throat doctors.

The company operates internationally, commercializing its technology across several European countries, including Germany, Switzerland, Spain, Finland, Austria, England, and the Netherlands, as well as the United States and Abu Dhabi. It maintains subsidiaries in Israel, Australia, the United States, and Germany. Nyxoah is headquartered in Mont-Saint-Guibert, Belgium.

Summary of the business section of Nyxoah's latest annual report, written by StockData.

Company profile

Company

Legal name
Nyxoah SA
Founded
2009
Headquarters
Mont-Saint-Guibert, Belgium
Address
Rue Edouard Belin 12 1435
Phone
(321) 022-2355
Website
nyxoah.com
Employees
50, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
C9
Fiscal year ends
December 31
Auditor
EY Reviseurs dEntreprises/ EY Bedrijfsrevisoren SRL/BV, Diegem, Belgium

Stock & identifiers

Ticker
NYXH
Exchange
Nasdaq
IPO date
Apr 28, 2021
Shares outstanding
43M, Dec 31, 2025
Filer category
Accelerated filer<br>Emerging growth company
SEC CIK
1857190
CUSIP
B6S7WD106
FIGI
BBG00ZKH4B03
Share class FIGI
BBG006JRTF01
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Nyxoah's leadership is listed in its proxy statement (Form DEF 14A).

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 6, 2021
Offer price
$30.00
Securities offered
2,835,000
Gross proceeds
$85.05M
Exchange
Nasdaq
Lock-up ends (est.)
Jan 2, 2022

“The initial public offering price is $30.00 per share, equivalent to an initial public offering price per share of &euro;25.13, assuming an exchange rate of &euro;1.00 = $1.194, the noon buying rate in The City of New York on June 25, 2021 set forth in the H.10 statistical release of the Federal Reserve”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had over 50 people in our commercial organization in the United States, of which 25 are sales representatives or territory managers that are supported by clinical education specialists, pre-authorization and reimbursement support personnel, customer service, marketing resources and leadership.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 28, 2021ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?